Published in J Immunol on December 15, 2006
Rapamycin and Regulatory T Cells in Kidney Transplantation | NCT01014234
FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 8.73
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27
Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 3.27
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 2.85
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Prediction and pathogenesis in type 1 diabetes. Immunity (2010) 2.26
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol (2010) 2.11
Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol (2007) 2.08
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 2.05
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood (2008) 1.95
Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost (2011) 1.91
CD28 costimulation is essential for human T regulatory expansion and function. J Immunol (2008) 1.86
Regulatory immune cells in transplantation. Nat Rev Immunol (2012) 1.82
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood (2009) 1.80
Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol (2008) 1.71
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Autoimmune polyglandular syndromes. Nat Rev Endocrinol (2010) 1.60
Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol (2012) 1.51
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes (2008) 1.49
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res (2011) 1.48
Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med (2011) 1.43
Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes (2011) 1.39
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica (2012) 1.39
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
mTOR: taking cues from the immune microenvironment. Immunology (2009) 1.38
Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant (2010) 1.36
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol (2010) 1.35
Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol (2008) 1.34
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer (2011) 1.33
Regulatory T cells in many flavors control asthma. Mucosal Immunol (2010) 1.28
Metabolic control of T cell activation and death in SLE. Autoimmun Rev (2008) 1.28
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One (2012) 1.26
Moving to tolerance: clinical application of T regulatory cells. Semin Immunol (2011) 1.25
Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol (2011) 1.23
Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol (2009) 1.20
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica (2011) 1.20
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes (2009) 1.18
Rapamycin unbalances the polarization of human macrophages to M1. Immunology (2013) 1.17
In vitro-generated antigen-specific CD4+ CD25+ Foxp3+ regulatory T cells control the severity of herpes simplex virus-induced ocular immunoinflammatory lesions. J Virol (2008) 1.16
Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle (2007) 1.15
Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun (2008) 1.14
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia (2014) 1.13
Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica (2012) 1.12
A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood (2012) 1.10
Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology (2010) 1.10
Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Mol Med (2011) 1.09
Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol (2013) 1.09
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res (2010) 1.08
CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur J Immunol (2013) 1.07
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy (2010) 1.04
Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol (2010) 1.03
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol (2014) 1.03
FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol (2015) 1.02
Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin J Am Soc Nephrol (2013) 1.01
Mechanism of cellular rejection in transplantation. Pediatr Nephrol (2010) 1.01
Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant (2012) 1.01
Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep (2013) 1.00
Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood (2015) 0.99
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol (2013) 0.99
Receptor signaling in immune cell development and function. Immunol Res (2011) 0.98
Thymic versus induced regulatory T cells - who regulates the regulators? Front Immunol (2013) 0.98
Autologous pancreatic islet transplantation in human bone marrow. Diabetes (2013) 0.97
Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Ther (2008) 0.96
Immunosuppression for lung transplantation. Front Biosci (Landmark Ed) (2009) 0.95
Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol (2012) 0.95
Natural regulatory T cells in autoimmunity. Autoimmunity (2010) 0.94
Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res (2014) 0.94
Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol (2008) 0.94
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer (2008) 0.94
T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol (2009) 0.94
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res (2013) 0.94
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica (2009) 0.93
mTOR Links Environmental Signals to T Cell Fate Decisions. Front Immunol (2015) 0.93
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans. Proc Natl Acad Sci U S A (2015) 0.93
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med (2012) 0.92
Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut (2015) 0.92
Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity (2010) 0.92
The Role of the PI3K Signaling Pathway in CD4(+) T Cell Differentiation and Function. Front Immunol (2012) 0.91
Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant (2012) 0.91
Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol (2012) 0.91
Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. Transplantation (2011) 0.90
Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol (2011) 0.90
Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. PLoS One (2009) 0.90
Tolerogenic therapies in transplantation. Front Immunol (2012) 0.88
Changing the energy of an immune response. Am J Clin Exp Immunol (2013) 0.88
Tregs and infections: on the potential value of modifying their function. J Leukoc Biol (2011) 0.88
Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. J Immunol (2010) 0.88
Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man. Front Immunol (2015) 0.88
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med (2002) 3.49
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39
Conditional disruption of beta 1 integrin in Schwann cells impedes interactions with axons. J Cell Biol (2002) 2.35
Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev (2006) 2.31
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol (2008) 2.18
Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 2.15
Tr1 cells: from discovery to their clinical application. Semin Immunol (2006) 2.05
Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J Clin Invest (2005) 1.92
WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med (2007) 1.77
Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol (2002) 1.76
Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity (2002) 1.69
Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes (2006) 1.65
Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol (2007) 1.61
Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood (2008) 1.58
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes (2008) 1.49
Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes (2006) 1.48
SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood (2005) 1.44
Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol (2006) 1.44
IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol (2006) 1.43
Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes (2011) 1.39
Comment on M. Guillot-Delost et al. (2008;10:834-846): Clinical-grade preparation of human natural regulatory T cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med (2009) 1.39
In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood (2009) 1.34
CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev (2005) 1.27
No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care (2010) 1.26
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica (2011) 1.20
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes (2009) 1.18
Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes (2013) 1.17
Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes (2009) 1.08
SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol (2005) 1.07
Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther (2004) 1.06
Suppressor of cytokine signaling 2 is a feedback inhibitor of TLR-induced activation in human monocyte-derived dendritic cells. J Immunol (2011) 1.04
An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. J Exp Med (2005) 1.04
IL-10-producing T regulatory type 1 cells and oral tolerance. Ann N Y Acad Sci (2004) 1.04
Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther (2006) 1.03
Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol (2006) 1.00
STAT6-dependent and -independent mechanisms in Th2 polarization. Eur J Immunol (2012) 0.95
Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells. Mol Ther (2012) 0.93
The diesel exhaust component pyrene induces expression of IL-8 but not of eotaxin. Int Immunopharmacol (2003) 0.92
Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. J Allergy Clin Immunol (2010) 0.92
Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS One (2011) 0.91
IL-4 and IL-13 induce SOCS-1 gene expression in A549 cells by three functional STAT6-binding motifs located upstream of the transcription initiation site. J Immunol (2003) 0.91
LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. J Biol Chem (2008) 0.91
Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther (2008) 0.91
Role of human leukocyte antigen-G in the induction of adaptive type 1 regulatory T cells. Hum Immunol (2009) 0.90
Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol (2012) 0.90
HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther (2011) 0.88
Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Semin Immunol (2011) 0.86
Modulation of T lymphocyte function by the pregnane X receptor. J Immunol (2010) 0.85
TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. Immunobiology (2012) 0.85
Reappraisal of in utero stem cell transplantation based on long-term results. Fetal Diagn Ther (2004) 0.84
Inhibition of suppressive T cell factor 1 (TCF-1) isoforms in naive CD4+ T cells is mediated by IL-4/STAT6 signaling. J Biol Chem (2010) 0.84
The puzzling world of murine T regulatory cells. Microbes Infect (2002) 0.84
Stabilization of the dimeric birch pollen allergen Bet v 1 impacts its immunological properties. J Biol Chem (2013) 0.84
Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunol Res (2009) 0.83
Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy. Front Microbiol (2011) 0.83
Identification of a distal tandem STAT6 element within the CCL17 locus. Hum Immunol (2007) 0.82
Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice. Diabetologia (2015) 0.82
Prolonged islet allograft survival in diabetic mice upon macrophage depletion by clodronate-loaded erythrocytes. Transplantation (2008) 0.81
Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. Novartis Found Symp (2008) 0.80
Patulin influences the expression of Th1/Th2 cytokines by activated peripheral blood mononuclear cells and T cells through depletion of intracellular glutathione. Environ Toxicol (2008) 0.79
The role of cytokines (and not only) in inducing and expanding T regulatory type 1 cells. Transplantation (2004) 0.78
Immunological lessons learnt from patients transplanted with fully mismatched stem cells. Immunol Res (2007) 0.77
Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Curr Opin Hematol (2005) 0.77